Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy

Thomas H Marwick1, Rebecca Ritchie1, Jonathan E Shaw1

  • 1Baker Heart and Diabetes Institute, Melbourne, Australia.

Insights

Diabetes and obesity increase heart failure risk, often with preserved ejection fraction. This review explores the complex links, focusing on molecular mechanisms and potential therapies for diabetic cardiomyopathy.

Area of Science:

  • Cardiology
  • Endocrinology
  • Molecular Biology

Background:

  • Heart failure incidence and prevalence rise with diabetes mellitus, pre-diabetes, and obesity.
  • Heart failure in these conditions often presents as heart failure with preserved ejection fraction, even without significant coronary artery disease.
  • The direct link to a primary diabetic cardiomyopathy is obscured by confounding factors like hypertension and autonomic neuropathy.

Purpose of the Study:

  • To review recent advances in understanding the molecular mechanisms of myocardial dysfunction in diabetes.
  • To discuss limitations in current knowledge and clinical screening for diabetic heart conditions.
  • To explore potential therapeutic strategies for heart failure associated with diabetes and metabolic disorders.

Main Methods:

  • Literature review of epidemiological, mechanistic, and clinical studies.
  • Analysis of systemic, cardiac, and cellular/molecular associations with heart dysfunction.
  • Synthesis of information on screening methods and therapeutic targets.

Main Results:

  • Epidemiological data strongly link diabetes to increased heart failure risk and poorer outcomes.
  • Mechanistic insights reveal impaired cardiac relaxation, compliance, and contractility due to diabetes.
  • Confounding factors complicate the definitive identification of a unique diabetic cardiomyopathy.

Conclusions:

  • Despite confounding factors, compelling evidence supports distinct myocardial changes in diabetes.
  • Further research into molecular pathways is crucial for developing targeted therapies.
  • Integrating molecular understanding with clinical practice is key to managing heart failure in diabetic populations.

Related Concept Videos

Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
372
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
591
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
377
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
534
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
606